Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Rapt Therapeutics (RAPT) to $4 from $17 and keeps an Overweight rating on the shares. The firm notes the FDA took the most conservative stance asking for definitive proof regarding liver SAE, contrary to expert expectations. Wells further notes efficacy signal from Phase 2b, which bodes well for next-gen compound, and awaits data to assess potential.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- Rapt Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- JPMorgan cuts Rapt Therapeutics to Underweight after zelnecirnon discontinued
- Rapt Therapeutics downgraded to Underweight from Neutral at JPMorgan
- Rapt Therapeutics model under review at Stifel after zelnecirnon discontinued
- Rapt Therapeutics terminates zelnecirnon program following clinical hold